Table 3.
In-vitro concentrations of 5-AZA-CdR that eradicate proliferative potential of solid tumor cells
| Tumor cell lines | IC 50 | Duration of treatment | References |
|---|---|---|---|
| HS-SY-II synovial sarcoma |
1.3 μM |
96 hours |
[84] |
| SYO-1 synovial sarcoma |
0.9 μM |
96 hours |
[84] |
| KB oropharyngeal cancer |
0.5 μM |
96 hours |
[85] |
| A549 lung adenocancer |
0.49 μM |
96 hours |
[85] |
| LoVo colon cancer |
0.4 μM |
96 hours |
[85] |
| LoVo-DX colon cancer |
0.1 μM |
96 hours |
[85] |
| MDA-MB- 435 breast cancer |
0.2 μM |
48 hours |
[83] |
| Hs578T breast cancer |
0.13 μM |
48 hours |
[87] |
| MCF-7 breast cancer |
0.13 μM |
48 hours |
[87] |
| MDA-MB- 231 breast cancer |
0.013 μM |
48 hours |
[83] |
| EMT6 mammary cancer |
0.22 μM |
18 hours |
[60] |
| Calu-6 lung cancer |
0.44 μM |
4-8 hours |
[60] |
| A(T1)C1-3 fibrosarcoma | 4.38 μM | 2 hours | [88] |
1 μM= 228 ng/ml. 5-AZA-CdR, 5-Aza-2′-deoxycytidine; IC50, half maximal inhibitory concentration.